Gen-Probe Reaches New 52-Week High (GPRO)

NEW YORK ( TheStreet) -- Gen-Probe (Nasdaq: GPRO) hit a new 52-week high Friday as it is currently trading at $82.26, above its previous 52-week high of $82.22 with 37,961 shares traded as of 9:35 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Gen-Probe has a market cap of $3.74 billion and is part of the services sector and diversified services industry. Shares are up 38.8% year to date as of the close of trading on Thursday.

Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. The company has a P/E ratio of 78.2, below the average diversified services industry P/E ratio of 79.7 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Gen-Probe as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Gen-Probe Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Time to Go Long GoPro?

Hurricane Irma, a Debt Deal and Disney Cause Wall Street Waves

Hurricane Irma Bears Down on Equities and Disney Slide Hits Dow

Stocks Seesaw as U.S. Prepares for Hurricane Irma and Recovers From Harvey

Hurricane Irma Prep, Harvey Recovery Set Wall Street on Edge